Centanafadine

Centanafadine
Systematic (IUPAC) name
(1R,5S)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane
Clinical data
Legal status
  • Investigational New Drug
Identifiers
CAS Number 924012-43-1
PubChem CID 16095349
ChemSpider 17253639
Chemical data
Formula C15H15N
Molar mass 209.28 g/mol

Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) under development by Neurovance in collaboration with Euthymics Bioscience as a treatment for attention deficit hyperactivity disorder (ADHD) that inhibits the reuptake of norepinephrine, dopamine and serotonin with a ratio of 1:6:14, respectively.[1][2][3] As of August 2015, it is in phase II clinical trials.

See also

References

External links



This article is issued from Wikipedia - version of the Friday, February 12, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.